Not Yet RecruitingNot Applicable

CPAP and Glucose Metabolism in Non-Diabetic OSA Subjects

Australia100 participantsStarted 2025-07-01

Plain-language summary

The purpose of the current study is to investigate whether alleviation of OSA by CPAP positively impacts glucose metabolism in non-diabetic patients.

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Community dwelling adult males and females aged 18-65 years
✓. Polysomnography confirmed moderate to severe OSA with apnea hypopnea index (AHI) ≥15/hr within the past 60 months
✓. Able to give written informed consent
✓. Proficient in English
✓. Fasting glucose with a BGL \<7.0 mmol/L
✓. Glucose tolerance with a 2-hour BGL of \< 11.1 mmol/L after a formal 75g Oral Glucose Tolerance Test (OGTT)
✓. HbA1C of ≤ 6.5% 7. Possession or regular access to a mobile telephone with capability to download and run the Withings Sleep Anlayser App.

✕. Clinically significant co-morbidity (e.g. myocardial infarction, congestive heart failure, stroke, arrythmia, chronic kidney or liver disease, epilepsy, head injury)
✕. Severe mental health disorders (e.g. current major depressive disorder, schizophrenia, bipolar disorder) that in the opinion of the investigator is not adequately treated or will significantly affect their participation in the study.
✕. Regular (\>2 times per month) use of sleep-affecting medication (e.g. benzodiazepines, opioids, antidepressants)
✕. Regular night shift work or travel overseas within the last 2 weeks
✕. Sleep physician has advised against CPAP withdrawal
✕. Pregnancy
✕. Active smoking or routine alcohol use (more than 2 standard drinks a day) or excessive caffeine intake (\>300 mg a day) or recent (in the past month) use of illicit drugs
✕. Current or previous diagnosis of diabetes mellitus (previous gestational diabetes mellitus not excluded)

Mean 24 hour glucose difference between the CPAP on and CPAP off conditions

Timeframe: 2 weeks

NCT IDNCT05335083

SponsorWoolcock Institute of Medical Research

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-02-28

David J Sherring, MBBS, DClinD

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Community dwelling adult males and females aged 18-65 years
✓. Polysomnography confirmed moderate to severe OSA with apnea hypopnea index (AHI) ≥15/hr within the past 60 months
✓. Able to give written informed consent
✓. Proficient in English
✓. Fasting glucose with a BGL \<7.0 mmol/L
✓. Glucose tolerance with a 2-hour BGL of \< 11.1 mmol/L after a formal 75g Oral Glucose Tolerance Test (OGTT)
✓. HbA1C of ≤ 6.5% 7. Possession or regular access to a mobile telephone with capability to download and run the Withings Sleep Anlayser App.

✕. Clinically significant co-morbidity (e.g. myocardial infarction, congestive heart failure, stroke, arrythmia, chronic kidney or liver disease, epilepsy, head injury)
✕. Severe mental health disorders (e.g. current major depressive disorder, schizophrenia, bipolar disorder) that in the opinion of the investigator is not adequately treated or will significantly affect their participation in the study.
✕. Regular (\>2 times per month) use of sleep-affecting medication (e.g. benzodiazepines, opioids, antidepressants)
✕. Regular night shift work or travel overseas within the last 2 weeks
✕. Sleep physician has advised against CPAP withdrawal
✕. Pregnancy
✕. Active smoking or routine alcohol use (more than 2 standard drinks a day) or excessive caffeine intake (\>300 mg a day) or recent (in the past month) use of illicit drugs
✕. Current or previous diagnosis of diabetes mellitus (previous gestational diabetes mellitus not excluded)